

Bonaventura Clotet Sala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8728163/publications.pdf>

Version: 2024-02-01

107
papers

4,860
citations

186265

28
h-index

102487

66
g-index

119
all docs

119
docs citations

119
times ranked

7896
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. <i>Cancers</i> , 2022, 14, 641.	3.7	7
2	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. <i>Cell Reports Medicine</i> , 2022, 3, 100523.	6.5	18
3	Comparison between mid-nasal swabs and buccal swabs for SARS-CoV-2 detection in mild COVID-19 patients. <i>Journal of Infection</i> , 2022, 84, e78-e79.	3.3	1
4	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> ,the, 2022, 10, 278-288.	10.7	61
5	Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. <i>EBioMedicine</i> , 2022, 78, 103956.	6.1	5
6	Remote Health Monitoring in the Workplace for Early Detection of COVID-19 Cases during the COVID-19 Pandemic Using a Mobile Health Application: COVIDApp.. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 167.	2.6	7
7	Prevalence, progression, and management of advanced chronic kidney disease in a cohort of people living with <sc>HIV</sc>. <i>HIV Medicine</i> , 2022, , .	2.2	0
8	Modulation of the autophagic pathway inhibits HIV-1 infection in human lymphoid tissue cultured ex vivo. <i>Scientific Reports</i> , 2022, 12, 7439.	3.3	4
9	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
10	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. <i>Frontiers in Immunology</i> , 2022, 13, 860215.	4.8	6
11	Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series. <i>Clinical Microbiology and Infection</i> , 2021, 27, 651-652.	6.0	5
12	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 187-191.	2.1	86
13	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 417-427.	27.0	179
14	Potential prescribing issues among older HIV-infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1310-1317.	2.4	8
15	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. <i>Scientific Reports</i> , 2021, 11, 2608.	3.3	86
16	Stable neutralizing antibody levels 6Âmonths after mild and severe COVID-19 episodes. <i>Med</i> , 2021, 2, 313-320.e4.	4.4	77
17	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. <i>Viruses</i> , 2021, 13, 1135.	3.3	17
18	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab329.	0.9	7

#	ARTICLE	IF	CITATIONS
19	Self-collected mid-nasal swabs and saliva specimens, compared with nasopharyngeal swabs, for SARS-CoV-2 detection in mild COVID-19 patients. <i>Journal of Infection</i> , 2021, 83, 709-737.	3.3	10
20	Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1365-1372.	9.1	73
21	Accentuated aging associated with HIV in a Mediterranean setting occurs mainly in persons aged >70 years: a comparative cohort study (Over50 cohort). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-8.	1.2	1
22	A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. <i>PLoS ONE</i> , 2020, 15, e0238575.	2.5	3
23	The Aging Imageomics Study: rationale, design and baseline characteristics of the study population. <i>Mechanisms of Ageing and Development</i> , 2020, 189, 111257.	4.6	18
24	ADAR1 Function Regulates Innate Immune Activation and Susceptibility to Viral Infections. <i>Proceedings (mdpi)</i> , 2020, 50, .	0.2	0
25	COVIDApp as an Innovative Strategy for the Management and Follow-Up of COVID-19 Cases in Long-Term Care Facilities in Catalonia: Implementation Study. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e21163.	2.6	39
26	Title is missing!. , 2020, 15, e0238575.		0
27	Title is missing!. , 2020, 15, e0238575.		0
28	Title is missing!. , 2020, 15, e0238575.		0
29	Title is missing!. , 2020, 15, e0238575.		0
30	Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. <i>Antiviral Research</i> , 2019, 168, 18-27.	4.1	8
31	Approach to amoebic colitis: Epidemiological, clinical and diagnostic considerations in a non-endemic context (Barcelona, 2007-2017). <i>PLoS ONE</i> , 2019, 14, e0212791.	2.5	26
32	Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up. <i>International Journal of STD and AIDS</i> , 2019, 30, 56-63.	1.1	4
33	Costâ€ effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2018, 36, 16-20.	0.5	6
34	Optimal Use of Transient Elastography and Acoustic Radiation Force Impulse to Stage Liver Fibrosis in HIV/HCVâ€Coinfected Patients in Clinical Practice. <i>Journal of Ultrasound in Medicine</i> , 2018, 37, 113-121.	1.7	4
35	Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. <i>Lancet HIV,the</i> , 2018, 5, e638-e646.	4.7	56
36	Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 929-934.	1.8	4

#	ARTICLE	IF	CITATIONS
37	CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. Nature Communications, 2018, 9, 2739.	12.8	61
38	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. Journal of Antimicrobial Chemotherapy, 2018, 73, 2452-2459.	3.0	6
39	ADAR1 affects HCV infection by modulating innate immune response. Antiviral Research, 2018, 156, 116-127.	4.1	27
40	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. Scientific Reports, 2017, 7, 40800.	3.3	12
41	Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. Scientific Reports, 2017, 7, 3717.	3.3	13
42	SAMHD1 is active in cycling cells permissive to HIV-1 infection. Antiviral Research, 2017, 142, 123-135.	4.1	18
43	RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages. Scientific Reports, 2017, 7, 13339.	3.3	43
44	Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery. Scientific Reports, 2017, 7, 11711.	3.3	12
45	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet, The, 2017, 390, 1499-1510.	13.7	391
46	Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men. American Journal of Men's Health, 2017, 11, 647-653.	1.6	19
47	Aging in HIV-Infected Subjects: A New Scenario and a New View. BioMed Research International, 2017, 2017, 1-9.	1.9	56
48	Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS ONE, 2017, 12, e0184433.	2.5	17
49	Epidemiological, clinical, diagnostic and economic features of an immigrant population of chronic schistosomiasis sufferers with long-term residence in a non-endemic country (North Metropolitan Tj ETQq1 1 0.784314 rgB2/Overlo	1.3	14
50	P-glycoprotein (<i>ABCB1</i>) activity decreases raltegravir disposition in primary CD4+P-gp ^{high} cells and correlates with HIV-1 viral load. Journal of Antimicrobial Chemotherapy, 2016, 71, 2782-2792.	3.0	16
51	Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity. BioMed Research International, 2016, 2016, 1-5.	1.9	7
52	The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells. PLoS Pathogens, 2016, 12, e1005829.	4.7	32
53	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw504.	3.0	9
54	Long-term HIV-1 infection induces an antiviral state in primary macrophages. Antiviral Research, 2016, 133, 145-155.	4.1	14

#	ARTICLE	IF	CITATIONS
55	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 171.	7.4	1,076
56	Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 1455-1472.	2.8	2
57	Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 463-483.	5.5	14
58	Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2564-2566.	3.2	15
59	Gut Microbiota Linked to Sexual Preference and HIV Infection. <i>EBioMedicine</i> , 2016, 5, 135-146.	6.1	328
60	Management of bone mineral density in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 845-852.	1.8	4
61	Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 387-394.	3.0	39
62	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 361-371.	0.5	10
63	Monotherapy with boosted PIs as an ART simplification strategy in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1124-1129.	3.0	13
64	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1139-1145.	3.0	21
65	Polymorphisms in <i>LPL</i> , <i>CETP</i> , and <i>HL</i> Protect HIV-Infected Patients from Atherogenic Dyslipidemia in an Allele-Dose-Dependent Manner. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 882-888.	1.1	5
66	Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 817-821.	1.1	10
67	Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1513-1516.	3.0	9
68	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. <i>Lancet HIV</i> , 2015, 2, e127-e136.	4.7	180
69	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 403-408.	5.8	100
70	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2104-2107.	3.0	25
71	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3087-3095.	3.0	13
72	Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients. <i>Antiviral Research</i> , 2015, 114, 48-52.	4.1	7

#	ARTICLE	IF	CITATIONS
73	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. <i>Journal of Infectious Diseases</i> , 2015, 211, 936-946.	4.0	18
74	Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. <i>PLoS ONE</i> , 2015, 10, e0128131.	2.5	4
75	Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. <i>Translational Lung Cancer Research</i> , 2015, 4, 678-88.	2.8	16
76	Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain. <i>Journal of Virus Eradication</i> , 2015, 1, 211-20.	0.5	0
77	Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject. <i>New Microbiologica</i> , 2015, 38, 193-9.	0.1	3
78	Classification Models for Neurocognitive Impairment in HIV Infection Based on Demographic and Clinical Variables. <i>PLoS ONE</i> , 2014, 9, e107625.	2.5	19
79	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e114142.	2.5	27
80	Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1 positive individuals: 96 week results from FLAMINGO. <i>Journal of the International AIDS Society</i> , 2014, 17, 19490.	3.0	41
81	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3368-3371.	3.0	43
82	Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance Testing. <i>Clinical Infectious Diseases</i> , 2014, 59, 578-588.	5.8	38
83	Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	4
84	Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. <i>Lancet</i> , The, 2014, 383, 2222-2231.	13.7	430
85	Zinc Finger Endonuclease Targeting <i>PSIP1</i> Inhibits HIV-1 Integration. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4318-4327.	3.2	15
86	Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells. <i>Journal of Immunology</i> , 2014, 193, 1988-1997.	0.8	118
87	Gene editing using a zinc-finger nuclease mimicking the CCR5 ^{Δ32} mutation induces resistance to CCR5-using HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1755-1759.	3.0	26
88	SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4804-4813.	3.2	30
89	Characterization of the Influence of Mediator Complex in HIV-1 Transcription. <i>Journal of Biological Chemistry</i> , 2014, 289, 27665-27676.	3.4	26
90	Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3057-3060.	3.0	26

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4A: a phase 2 randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 291-300.	9.1	100
92	Detection of a Sexually Transmitted Hepatitis C Virus Protease Inhibitor-Resistance Variant in a Human Immunodeficiency Virus-Infected Homosexual Man. <i>Gastroenterology</i> , 2014, 147, 599-601.e1.	1.3	59
93	Association between lipid genetic and immunological status in chronically HIV-infected patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19555.	3.0	1
94	Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. <i>Journal of the International AIDS Society</i> , 2014, 17, 19557.	3.0	2
95	Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study. <i>PLoS ONE</i> , 2014, 9, e84676.	2.5	11
96	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e87334.	2.5	15
97	Functional Analyses Reveal Extensive RRE Plasticity in Primary HIV-1 Sequences Selected under Selective Pressure. <i>PLoS ONE</i> , 2014, 9, e106299.	2.5	4
98	Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. <i>Future Virology</i> , 2012, 7, 1127-1134.	1.8	3
99	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. <i>Vaccine</i> , 2011, 29, 5250-5259.	3.8	38
100	Differences in Virological Response to Pegylated Interferon and Ribavirin between Hepatitis C Virus (Hcv)-Monoinfected and HCV-Hiv-Coinfected Patients. <i>Antiviral Therapy</i> , 2008, 13, 1047-1055.	1.0	22
101	Clinical approach to drug resistance interpretation: expert advice. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 145-149.	3.8	1
102	Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses. <i>Journal of General Virology</i> , 2006, 87, 1285-1294.	2.9	13
103	3-Azido-2,3-Dideoxythymidine (Zidovudine) Uptake Mechanisms in T Lymphocytes. <i>Antiviral Therapy</i> , 2006, 11, 803-812.	1.0	18
104	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. <i>Antiviral Therapy</i> , 2005, 10, 791-802.	1.0	55
105	Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death. <i>Antiviral Therapy</i> , 2003, 8, 155-161.	1.0	25
106	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. <i>Antiviral Therapy</i> , 2003, 8, 1-8.	1.0	51
107	EOSINOPHILIC PUSTULAR FOLLICULITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME. <i>International Journal of Dermatology</i> , 1992, 31, 193-195.	1.0	53